Sign in
Taking people in United StatesPhase 2

CMV vaccine for stem cell donors to protect transplant patients with blood cancers

Tests a CMV vaccine in stem cell donors for transplant patients.

Key facts

Who runs it
City of Hope Medical Center
Where
Atlanta, Boston, and Duarte, United StatesSee the 3 sites
Trial code
Registry title
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Status
Recruiting
Phase
Phase 2
People taking part
216 people, planned
Started
9 Jul 2024
Expected to end
1 Jan 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • Biospecimen Collection
  • Granulocyte Colony-Stimulating Factor
  • Hematopoietic Cell Transplantation Conditioning Regimen
  • Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
  • Pheresis
  • Placebo Administration
  • Stem Cell Mobilization Therapy
Record updated
23 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for two groups: adult family stem cell donors, and adult patients with blood cancers who are planned for a stem cell transplant from a fully tissue-matched related donor. Donors get a CMV vaccine or placebo before donating.

Age
Donors: 18 and above. Recipients: 18 and above. The registry lists a maximum age of 75 years.
Sex
All sexes can join.
Disease stage
Recipients: Hodgkin or non-Hodgkin lymphoma, myelodysplastic syndrome, acute lymphoblastic or acute myeloid leukemia in first or second remission, chronic myeloid leukemia in first or second chronic phase or accelerated phase, chronic lymphocytic leukemia, myeloproliferative disorders or myelofibrosis. Multiple myeloma is excluded.
Earlier treatment
Recipients: no earlier donor stem cell transplant, no earlier experimental CMV vaccine, no experimental anti-CMV chemotherapy in the last 6 months, and no antiviral drugs against CMV. Donors: no earlier transplant, and no chemotherapy, radiation or immunotherapy within 21 days.
Biomarker or test result
Recipients must be CMV seropositive. The planned donor must be a related person with 8/8 high-resolution HLA allele matching (A, B, C, DRB1).

Main reasons for not taking part

  • Recipients: autoimmune disease
  • Recipients: pregnant or breastfeeding women
  • Recipients: alemtuzumab or similar drugs that remove T-cells
  • Donors: HIV, active hepatitis B or C, or HTLV-I/II
  • Donors: sickle cell disease or sickle cell trait, or impaired heart function

The registry criteria, word for word

Show all 46 criteriaShow less

Who can take part

  • DONORS: Documented informed consent of the participant and/or legally authorized representative; Assent, when appropriate, will be obtained per institutional guidelines
  • DONORS: Age: 18 and above
  • RECIPIENTS: Documented informed consent of the participant and/or legally authorized representative; Assent, when appropriate, will be obtained per institutional guidelines
  • RECIPIENTS: Participant must be willing to comply with study and/or follow-up procedures, including willingness to be followed for one year post-HCT
  • RECIPIENTS: Age: 18 and above
  • RECIPIENTS: Karnofsky performance score ≥ 70 or ECOG ≤ 2
  • RECIPIENTS: Planned HCT for the treatment of the following hematologic malignancies: lymphoma (Hodgkin and Non-Hodgkin), myelodysplastic syndrome, acute lymphoblastic leukemia in first or second remission, acute myeloid leukemia in first or second remission, chronic myelogenous leukemia (in first chronic or accelerated phase, or in second chronic phase), chronic lymphocytic leukemia, myeloproliferative disorders and myelofibrosis. Patients with multiple myeloma are excluded
  • RECIPIENTS: CMV seropositive
  • RECIPIENTS: Planned related HCT with 8/8 (A, B, C, DRB1) high resolution human leukocyte antigen (HLA) donor allele matching
  • RECIPIENTS: Conditioning and immunosuppressive regimens according to institutional guidelines are permitted. Patients may receive myeloablative, reduced intensity, or nonmyeloablative conditioning
  • RECIPIENTS: Total bilirubin ≤ 2 X upper limit of normal (ULN) (unless has Gilbert's disease)
  • RECIPIENTS: Aspartate aminotransferase (AST) ≤ 2.5 x ULN
  • RECIPIENTS: Alanine aminotransferase (ALT) ≤ 2.5 x ULN
  • RECIPIENTS: Creatinine clearance of ≥ 60 mL/min per 24 hour urine test or the Cockcroft-Gault formula
  • RECIPIENTS: Left ventricular ejection fraction (LVEF) ≥ 50% Note: To be performed within 45 days prior to day 1 of protocol therapy
  • RECIPIENTS: If able to perform pulmonary function tests: forced vital capacity (FVC) and diffusion capacity of carbon monoxide (DLCO) (diffusion capacity) ≥ 50% of predicted (corrected for hemoglobin). If unable to perform pulmonary function tests: oxygen (O2) saturation > 92% on room air Note: To be performed within 45 days prior to day 1 of protocol therapy
  • RECIPIENTS: Seronegative for human immunodeficiency virus (HIV) antigen (Ag)/antibody (Ab) combo, hepatitis C virus (HCV)*, active hepatitis B virus (HBV) (surface antigen negative), and syphilis (rapid plasma reagin [RPR]); If seropositive for HIV, HCV or HBV, nucleic acid quantitation must be performed. Viral load must be undetectable
  • RECIPIENTS: Meets other institutional and federal requirements for infectious disease titer requirements Note: Infectious disease testing to be performed within 45 days prior to day 1 of protocol therapy
  • RECIPIENTS: Women of childbearing potential (WOCBP): Negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  • RECIPIENTS: Agreement by females and males of childbearing potential* to use an effective method of birth control (hormonal or barrier method) or abstain from heterosexual activity prior to study entry and for up to 90 days post-HCT; Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)

Who cannot take part

  • DONORS: Any prior transplant to day 1 of protocol therapy
  • DONORS: Chemotherapy, radiation therapy, biological therapy, immunotherapy within 21 days prior to day 1 of protocol therapy
  • DONORS: Receipt of any vaccine (licensed or investigational) within 30 days prior to and after of the study vaccine
  • RECIPIENTS: Any prior investigational CMV vaccine
  • RECIPIENTS: Experimental anti-CMV chemotherapy in the last 6 months
  • RECIPIENTS: Prior allogeneic (allo) transplant for any condition
  • RECIPIENTS: Live attenuated vaccines
  • RECIPIENTS: Medically indicated subunit (Engerix-B for HBV; Gardasil for HPV) or killed vaccines (e.g. influenza, pneumococcal, or allergy treatment with antigen injections)
  • RECIPIENTS: Allergy treatment with antigens injections
  • RECIPIENTS: Antiviral medications with known therapeutic effects on CMV such as valganciclovir/ganciclovir (GCV/VAL), foscarnet (FOS), cidofovir, brincidofovir (CMX-001), maribavir. Acyclovir has no known therapeutic efficacy against CMV and is allowable as standard of care to prevent herpes simplex virus (HSV)
  • RECIPIENTS: Prophylactic therapy with CMV immunoglobulin or prophylactic antiviral CMV treatment
  • RECIPIENTS: Other investigational product - concurrent enrollment in other clinical trials using any investigational new drug (IND) drugs with unknown effects on CMV or with unknown toxicity profiles is prohibited
  • RECIPIENTS: Other medications that might interfere with the evaluation of the investigational product
  • DONORS: Positive for HIV, active hepatitis B (HBV), hepatitis C (HCV) or human T-cell lymphotropic virus (HTLV-I/II)
  • DONORS: Severe psychiatric illness. Mental deficiency sufficiently severe as to make compliance with the donation procedure unlikely, and making informed consent impossible
  • DONORS: Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
  • RECIPIENTS: Diagnosis with autoimmune disease
  • RECIPIENTS: Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
  • DONORS: Unfit to undergo standard stem cell mobilization and apheresis e.g. abnormal blood counts, history of stroke, uncontrolled hypertension
  • DONORS: Sickling hemoglobinopathy including hemoglobin S (HbSS), sickle cell trait (HbAS), hemoglobin sickle C disease (HbSC)
  • DONORS: Donors with impaired cardiac function are excluded. Electrocardiography is routine for potential HCT donors over 60 years old and those with a history of heart disease. Subjects in whom cardiac function is abnormal (excluding 1st degree branch block, sinus bradycardia, sinus tachycardia or non-specific T wave changes) are ineligible for Triplex vaccination
  • DONORS: Females only: Pregnant or breastfeeding
  • DONORS: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
  • RECIPIENTS: Alemtuzumab or any equivalent in vivo T-cell depleting agent
  • RECIPIENTS: Females only: Pregnant women and women who are lactating. The risks of Triplex to pregnant women are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother. Breastfeeding should be discontinued if the mother is enrolled on this study
  • RECIPIENTS: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United States

  • Northside HospitalAtlanta, United StatesContact: Scott R. Solomon, MDTaking people
  • DFCI/BWH Brigham and Women's HospitalBoston, United StatesContact: Lindsey Baden, MDTaking people
  • City of Hope Medical CenterDuarte, United StatesContact: Vaibhav AgrawalTaking people

About the trial

What the trial wants to find out

This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients undergoing hematopoietic stem cell transplant. The CMV-MVA Triplex vaccine works by causing an immune response in the donors body to the CMV virus, creating immunity to it. The donor then passes that immunity on to the patient upon receiving the stem cell transplant. Giving the CMV-MVA triplex vaccine to donors may help prevent CMV infection of patients undergoing stem cell transplantation.

The 2 groups in the trial

  • Arm I (Triplex vaccination)Treatment being tested

    DONORS: Donors receive Triplex vaccine IM on day 0 and then undergo stem cell mobilization with G-CSF on days 5 to 9 and apheresis for peripheral blood stem cell collection on days 10 to 14 per standard of care. Donors may optionally undergo blood sample collection on study. RECIPIENTS: Recipients undergo pre-transplant conditioning on days -60 to 0 and undergo HCT with the donor peripheral blood stem cells within 9 weeks of donor vaccination on day 0. Recipients undergo blood sample collection on study.

    Treatment: Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Granulocyte Colony-Stimulating Factor, Hematopoietic Cell Transplantation Conditioning Regimen, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Pheresis, and Stem Cell Mobilization Therapy

  • Arm II (Placebo)Placebo, for comparison

    DONORS: Donors receive placebo IM on day 0 and undergo stem cell mobilization with G-CSF on days 5 to 9 and apheresis for peripheral blood stem cell collection on days 10 to 14 per standard of care. Donors may optionally undergo blood sample collection on study. RECIPIENTS: Recipients undergo pre-transplant conditioning on days -60 to 0 and undergo HCT with the donor peripheral blood stem cells within 9 weeks of donor vaccination on day 0. Recipients undergo blood sample collection on study.

    Treatment: Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Granulocyte Colony-Stimulating Factor, Hematopoietic Cell Transplantation Conditioning Regimen, Pheresis, Placebo Administration, and Stem Cell Mobilization Therapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Placebo-Controlled and Randomized Phase 2 Trial of CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors to Enhance CMV-Specific Immunity and Prevent CMV Viremia in Recipients After Hematopoietic Stem Cell Transplant
Plain-language title
CMV vaccine for stem cell donors to protect transplant patients with blood cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06059391, who can take part
Record updated
23 October 2026